BioCentury
ARTICLE | Company News

IQWiG finds marginal additional benefit for Bayer's Stivarga

January 3, 2014 12:53 AM UTC

Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) said Stivarga regorafenib from Bayer AG (Xetra:BAYN) has "marginal" additional benefit vs. best supportive care (BSC) to treat metastatic colorectal cancer (mCRC). IQWiG said Stivarga improved survival, but noted that patients also experienced side effects including fatigue and diarrhea more frequently. Comments are due Jan. 23, with a final assessment from Germany's Federal Joint Committee (G-BA) expected in mid-March. ...